Archive | November, 2014

Chemotherapy-induced cardiotoxicity: Who Will Get Chemotherapy-Induced Cardiotoxicity?

  Many of the chemotherapeutic agents in use today can have associated cardiovascular side effects, the most common of which are cardiomyopathy and heart failure (HF). Amongst the various medications, the anthracycline class of drugs (e.g., doxorubicin and epirubicin) and the human epidermal growth factor receptor type 2 (HER 2) monoclonal antibody, trastuzumab, have been […]

Leave a comment Continue Reading →

Myocardial Strain Imaging by Echocardiography for the Early Detection of Chemotherapy-induced Cardiotoxicity

The mortality rate among patients with cancer has decreased over the past 20 to 30 years. However, cardiac toxicity (cardiotoxicity) from cancer therapy has become a leading cause of morbidity and mortality in survivors. In patients who develop heart failure (HF) from cancer therapy, the mortality rate is as high as 60% by 2 years. […]

Leave a comment Continue Reading →

In non–ST elevation acute coronary syndrome with and without percutaneous coronary intervention, pretreatment with thienopyridines did not reduce mortality and was associated with increased risk for major bleeding

To investigate the effect of pretreatment with P2Y12 receptor inhibitors compared with no pretreatment on efficacy and safety of treatment of non-ST elevation acute coronary syndrome (ACS). The authors of this paper report the results of a pooled analysis of randomized and observational studies of pretreatment with thienopyridines (clopidogrel or prasugrel) vs no pretreatment in […]

Leave a comment Continue Reading →

Antibiotic associated with increased risk for sudden death in patients taking ACE inhibitors or ARBs

  Trimethoprim/sulfamethoxazole (or co-trimoxazole) was associated with an increased risk of sudden death in older patients receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), a study found (published online Oct. 30, 2014 by BMJ). Researchers conducted a population-based, nested, case-control study in Ontario, Canada, from April 1994 to January 2012 among patients age 66 […]

Leave a comment Continue Reading →